FDA releases Dexcom warning letter; Stent use delay could aid in a cardiac patient's recovery;

@FierceMedDev: An analyst thinks Smith & Nephew should split into three pieces, and investors loved the idea. Story | Follow @FierceMedDev

@MarkHFierce: Check out FierceBiotech's debut EuroBiotech report. Report | Follow @MarkHFierce

@MichaelGFierce: Small, drug-releasing battery could dissolve completely over time. Article via FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: GN Store Nord's U.S. customer base gets a boost thanks to its bluetooth-like hearing aid. Article | Follow @EmilyWFierce

> Diagnostics outfit LipoScience has ended its relationship with Health Diagnostics Laboratory, one of its customers, after HDL began offering a similar test to LipoScience's offering. Story

> The FDA released the warning letter it issued to Dexcom ($DXCM), which offers details including an instance where its blood glucose monitor shocked a patient. Story

> A new Ohio device startup is developing technology that could more quickly sterilize surgical instruments and implants. Story

> U.K. researchers have determined that delaying the use of a stent for up to 16 hours after a heart attack (where blood flow has been restored) can aid in patients' recovery. Story

Biotech News

@FierceBiotech: Our 1st EuroBiotech Report: Merck KGaA R&D chief exits, Sobi drug flops in PhIII, Adaptimmune gets full-time CEO. Report | Follow @FierceBiotech

@JohnCFierce: Novartis is using Twitter to support its R&D team at adcomms? Social media won't substitute for another serelaxin trial. More | Follow @JohnCFierce

@DamianFierce: Syndax swings for a $69M IPO with 'breakthrough' drug in tow. News | Follow @DamianFierce

@EmilyMFierce: Report: U.S. can do more to support global health R&D. Article via FierceBiotech Research | Follow @EmilyMFierce

> Ebola still a tough target due to Big Pharma disinterest and few outbreaks. More

> MannKind faces stiff skepticism in its third go at FDA approval. Story

> AstraZeneca looks to China for kidney disease R&D. Item

Pharma News

@FiercePharma: Top-read FP story yesterday: Merck, GlaxoSmithKline halt copay help for Obamacare patients. Story |  Follow @FiercePharma

@TracyStaton: RT: Just out: today's full issue of FiercePharmaMarketing. More | Follow @TracyStaton

@EricPFierce: FDA's Woodcock throws cold water on research that found foreign-made generics of Lipitor tainted. Article | Follow @EricPFierce

@CarlyHFierce: Check out FierceBiotech's new EuroBiotech report, which will run every Friday from here on out. Report | Follow @CarlyHFierce

> Roche nabs European approval for time-saving formulation of Rituxan. More

> Hospira puts shareholder lawsuit behind it with $60M settlement. News

> Regeneron clears roadblock for new plant in Irish tax haven. Story

Suggested Articles

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.